Related Experiment Video
Updated: Mar 23, 2026

Ascending Aortic Constriction in Rats for Creation of Pressure Overload Cardiac Hypertrophy Model
Published on: June 29, 2014
Angiotensin II Stimulation of Cardiac Hypertrophy and Functional Decompensation in Osteoprotegerin-Deficient Mice
Toshihiro Tsuruda1, Yoko Sekita-Hatakeyama2, Yilin Hao2
1From the Department of Internal Medicine, Circulatory and Body Fluid Regulation (T.T., Y.S.-H., Y.H., S.S., K.K.), Division of Orthopaedic Surgery, Department of Medicine of Sensory and Motor Organs (S.K., T.F., T.S., E.C.), Department of Pathology (Y.A.), Frontier Science Research Center (J.K.), Faculty of Medicine, University of Miyazaki, Miyazaki, Japan; Department of Biochemistry, Matsumoto Dental University, Nagano, Japan (M.N., N.U.); and Department of Diagnostic Pathology, Nara Medical University, Nara, Japan (K.H.). ttsuruda@med.miyazaki-u.ac.jp.
Insights
Osteoprotegerin protects against angiotensin II-induced heart failure by preserving myocardial structure and function. This effect is independent of receptor activator of nuclear factor-κb ligand activity, highlighting osteoprotegerin
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Renal Physiology
Background:
- Receptor activator of nuclear factor-κb ligand (RANKL) and osteoprotegerin (OPG) are implicated in heart failure.
- Their specific roles in left ventricular remodeling, particularly with the renin-angiotensin system, require elucidation.
Purpose of the Study:
- To investigate the pathophysiological roles of OPG and RANKL in angiotensin II-induced left ventricular remodeling.
- To determine if OPG or RANKL influence cardiac structure and function during hypertrophy.
Main Methods:
- Utilized osteoprotegerin knockout mice and RANKL-transgenic mice.
- Administered angiotensin II via subcutaneous infusion to induce cardiac remodeling.
- Assessed left ventricular structure, systolic function, fibrosis, and apoptosis.
- Investigated the effects of OPG administration and anti-RANKL antibody treatment.
Main Results:
- Angiotensin II induced eccentric hypertrophy and systolic dysfunction in OPG-deficient mice, with reduced fibrosis and increased apoptosis.
- RANKL-transgenic mice exhibited concentric hypertrophy with preserved systolic function.
- Recombinant OPG treatment ameliorated heart failure progression in OPG-deficient mice without impacting blood pressure.
Conclusions:
- Osteoprotegerin plays a protective role in mitigating angiotensin II-induced cardiac hypertrophy and dysfunction.
- OPG's beneficial effects appear independent of RANKL activity.
- OPG may exert cardioprotective mechanisms through anti-apoptotic and profibrotic actions.
Abstract:
Circulating and myocardial expressions of receptor activator of nuclear factor-κb ligand and osteoprotegerin are activated in heart failure; however, it remains to be determined their pathophysiological roles on left ventricular structure and function in interaction with renin-angiotensin system. We conducted experiments using 8-week-old osteoprotegerin(-/-) mice and receptor activator of nuclear factor-κb ligand-transgenic mice to assess whether they affect the angiotensin II-induced left ventricular remodeling. Subcutaneous infusion of angiotensin II to osteoprotegerin(-/-) mice progressed the eccentric hypertrophy, resulting in left ventricular systolic dysfunction for 28 days, and this was comparable with wild-type mice, showing concentric hypertrophy, irrespective of equivalent elevation of systolic blood pressure. The structural alteration was associated with reduced interstitial fibrosis, decreased procollagen α1 and syndecan-1 expressions, and the increased number of apoptotic cells in the left ventricle, compared with wild-type mice. In contrast, angiotensin II infusion to the receptor activator of nuclear factor-κb ligand-transgenic mice revealed the concentric hypertrophy with preserved systolic contractile function. Intraperitoneal administration of human recombinant osteoprotegerin, but not subcutaneous injection of anti-receptor activator of nuclear factor-κb ligand antibody, to the angiotensin II-infused osteoprotegerin(-/-) mice for 28 days ameliorated the progression of heart failure without affecting systolic blood pressure. These results underscore the biological activity of osteoprotegerin in preserving myocardial structure and function during the angiotensin II-induced cardiac hypertrophy, independent of receptor activator of nuclear factor-κb ligand activity. In addition, the antiapoptotic and profibrotic actions of osteoprotegerin that emerged from our data might be involved in the mechanisms.
Related Concept Videos
Heart Failure II: Pathophysiology
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Hypertension II: Pathophysiology

